SCHEMBL2998832

SCHEMBL2998832

CCCc1cc(C(=O)NN)ccn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.64
CYP3A4 P08684 3/20 0.64
LMNA P02545 1/20 0.64
TSHR P16473 1/20 0.64
CYP1A2 P05177 2/20 0.49
POLB P06746 1/20 0.49
MPO P05164 2/20 0.49
ADORA3 P0DMS8 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2A6 P11509 1/20 0.49
CYP2C19 P33261 1/20 0.49
KDM5A P29375 4/20 0.43
KDM5C P41229 2/20 0.43
KDM5B Q9UGL1 2/20 0.43
ALDH1A1 P00352 2/20 0.41
SREBF2 Q12772 1/20 0.40
KDM5D Q9BY66 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
PRKCI P41743 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2405138 0.89 KDM4E (0.51) KDM4ECYP3A4LMNATSHRCYP1A2
SCHEMBL28289385 0.88 KDM4E (0.50) KDM4ECYP3A4LMNATSHRCYP1A2
SCHEMBL4009980 0.88 KDM4E (0.50) KDM4ECYP3A4LMNATSHRCYP1A2
SCHEMBL18370157 0.87 KDM4E (0.59) KDM4ECYP3A4LMNATSHRCYP1A2
SCHEMBL2989555 0.87 CYP1A2 (0.60) KDM4ECYP3A4LMNATSHRCYP1A2
Protionamide SCHEMBL28086439 0.84 KDM4E (0.51) KDM4ECYP3A4LMNATSHRCYP1A2
SCHEMBL17873933 0.83 KDM4E (0.73) KDM4ECYP3A4LMNATSHRCYP1A2
SCHEMBL16055756 0.81 KDM4E (0.65) KDM4ECYP3A4LMNATSHRCYP1A2
SCHEMBL18930028 0.81 LMNA (0.52) KDM4ECYP3A4LMNATSHRALDH1A1
SCHEMBL3643495 0.81 KDM4E (0.59) KDM4ECYP3A4LMNATSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) 2010-07-22 US disclosed
EP-2068873-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS Pharma 2100 (DK) 2009-06-17 EP disclosed
WO-2008031440-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS PHARMA 2100 (DK) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS ODC1, OTC, ACACB KDM4E 3169/4885CYP3A4 488/4885LMNA 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.